A Form 4 filed with the SEC on September 15, 2026 discloses that Marino Garcia, a director of AgomAb Therapeutics NV (NASDAQ:AGMB), was granted stock options on September 11, 2026.

Key Highlights

  • Reporting person: Marino Garcia, identified as a director of AgomAb Therapeutics NV.
  • Option grant: 57,482 stock options (Right to Buy) were acquired on September 11, 2026, with a transaction code of A (acquired).
  • Exercise price: $13.94 per share, reflecting a conversion from EUR to USD at an exchange rate of $1.1616 per EUR 1.00 as of September 10, 2026.
  • Expiration date: January 15, 2036, according to the filing.
  • Vesting schedule: 33% of the shares vest on September 11, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to continued service.
  • Beneficial ownership following transaction: 57,482 derivative securities held directly.

Director Option Award Details for AgomAb Therapeutics NV

According to the Form 4 filed on September 15, 2026, Marino Garcia, a director of AgomAb Therapeutics NV, received a stock option grant dated September 11, 2026. The filing reports that Garcia acquired 57,482 stock options (Right to Buy) at an exercise price of $13.94 per share. The filing notes that the exercise price "is reported in U.S. dollars and reflects the conversion from EUR to USD at an exchange rate of $1.1616 per EUR 1.00 as of September 10, 2026."

The underlying security is described as common shares, and the filing notes that "the common shares may be represented by American Depositary Shares, each of which currently represents one common share." The options are set to expire on January 15, 2036, and the price of the derivative security is reported as $0.00. Following the reported transaction, Garcia beneficially owns 57,482 derivative securities directly.

Regarding the vesting terms, the filing states that "33% of the shares underlying this option shall vest on September 11, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date." The Form 4 was signed by Ellen Lefever as Attorney-in-Fact on September 15, 2026.

What Was Disclosed

AgomAb Therapeutics NV director Marino Garcia acquired 57,482 stock options on September 11, 2026, at an exercise price of $13.94, expiring January 15, 2036, with a multi-year vesting schedule tied to continued service, as reported in a Form 4 filed September 15, 2026.